StoryFunding
Insilico Medicine completes IPO on Hong Kong Stock Exchange, raising $293 million
Insilico Medicine went public on the Hong Kong Stock Exchange in December 2025, raising approximately $293 million. This IPO marks a major milestone for the company's AI drug discovery platform, allowing it to accelerate its pipeline and fund partnerships.